Naimish Patel - 20 Mar 2026 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CRSP
Reported as of: 20 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Mar 2026, 17:36:41 UTC
Prior SEC filing: 17 Mar 2026
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: Elizabeth Ryland Waldinger, attorney-in-fact

Key filing fact

Naimish Patel filed Form 4 for CRISPR Therapeutics AG (CRSP) on 24 Mar 2026.

Key facts

This page summarizes Naimish Patel's Form 4 filing for CRISPR Therapeutics AG (CRSP).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 24 Mar 2026, 17:36.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002021679 Primary reporting owner

Patel Naimish

Relationship: Chief Medical Officer
Address: C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON
Signature: Elizabeth Ryland Waldinger, attorney-in-fact
Signature date: 24 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRSP transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +38,499
Change %
Price: $0.000000^*
Shares after: 38,499
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 38,499
Exercise price: $46.24
Footnotes: F1, F2

CRSP transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 20 Mar 2026
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 30,000
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

Footnote F2

This option was granted on March 20, 2026 with respect to 38,499 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 20, 2026.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

Footnote F4

This restricted stock unit award was granted on March 20, 2026 with respect to 30,000 Common Shares, with (i) one quarter of the shares vesting on March 20, 2027 , (ii) one quarter of the shares vesting on March 20, 2028, (iii) one quarter of the shares vesting on March 20, 2029, and (iv) one quarter of the shares vesting on March 20, 2030.